Home › Hidradenitis Suppurativa › Arizona › Phoenix
Hidradenitis Suppurativa clinical trials in Phoenix, AZ
5 studies for Hidradenitis Suppurativa are looking for participants at sites in and around Phoenix (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
- Investigative Site US004, Phoenix
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RecruitingPhase 1
- Saguaro Dermatology, Phoenix
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
- Medical Dermatology Specialists - Site Number: 8400019, Phoenix
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
- Medical Dermatology Specialists Phoenix, Phoenix
- Saguaro Dermatology, Phoenix
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RecruitingPhase 2
- Medical Dermatology Specialist, Phoenix
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
More about Hidradenitis Suppurativa on MedlinePlus
Hidradenitis Suppurativa trials in other cities
- Boston, MA9 studies
- Tampa, FL7 studies
- Miami, FL6 studies
- New York City, NY5 studies
- Dallas, TX5 studies
- Birmingham, AL5 studies
- Philadelphia, PA4 studies
- Durham, NC4 studies
- Minneapolis, MN4 studies
- Santa Clarita, CA4 studies
- New Orleans, LA4 studies
- Scottsdale, AZ4 studies
Other studies in Phoenix
- Breast Cancer25 studies
- Colorectal Cancer25 studies
- Obesity22 studies
- Non-Small Cell Lung Cancer20 studies
- Metastatic Cancer20 studies
- Heart Failure18 studies
- Prostate Cancer17 studies
- Cancer (all types)17 studies
- Multiple Myeloma16 studies
- Pancreatic Cancer16 studies
- Cardiovascular Disease16 studies
- Alzheimer's Disease15 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.